摘要
背景:链脲霉素(STZ)的双侧侧脑室(ICV)注射导致大鼠阿尔茨海默病(AD)型神经退化。这种模型正越来越多地被用于研究AD病理和治疗策略。目的:本研究目的在于探究STZ-ICV注射的老鼠在60天时间内,其认知能力和海马与皮质线粒体功能的关系。方法:使用不同的迷宫检测老鼠认知能力。在线粒体三态呼吸、复合体-I活动和发动相关蛋白-1(DRP-1)的表式分别用oxygraph液相氧电极,分光光度法和免疫印迹试验测量。采用刚果红染色对淀粉样变性进行研究。结果:一次性ICV-STZ注射的动物表现出体重下降并且注射第14天后认知能力受损。注射14天后直到第60天,在海马和皮质中,线粒体电子传递链复合体-1活性严重下降。而注射第14天线粒体3态呼吸在这些大脑区域没有改变,从第21天以后显著降低。灌注后21天后,这些动物的海马和皮质中DRP-1表达显著增加在,但只持续到第60天。21天后,在海马体中检测到淀粉样变噬刚果红颗粒。结论:本研究结果表明,单次STZ-ICV注射的非遗传散发性AD(sAD)大鼠模型表现出蛋白质聚集和痴呆症,这可能是由于线粒体分裂增多和功能异常所致。本研究证实了利用这种模型研究sAD的发病机理和潜在疗法的有效性。
关键词: 淀粉样变性,认知功能丧失,发动相关蛋白1,线粒体呼吸下降,非转基因动物模型,散发性阿尔茨海默病模型。
Current Alzheimer Research
Title:Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin
Volume: 12 Issue: 8
Author(s): Ramesh K. Paidi, Dominic N Nthenge-Ngumbau, Raghavendra Singh, Thulasi Kankanala, Hina Mehta and Kochupurackal P. Mohanakumar
Affiliation:
关键词: 淀粉样变性,认知功能丧失,发动相关蛋白1,线粒体呼吸下降,非转基因动物模型,散发性阿尔茨海默病模型。
摘要: Background: Bilateral intracerebroventricular (ICV) administration of streptozotocin (STZ) causes Alzheimer’s disease (AD)-type neurodegeneration in rats. The model is increasingly used for investigating pathology and therapeutic strategies for AD. Objective: The present study investigated cognitive abilities in rats infused with STZ-ICV in relation to hippocampal and cortical mitochondrial functions during a period of 60 days. Methods: Cognitive functions were assayed in rats employing various mazes. Mitochondrial state-3-respiration, complex-I activity and dynamin related protein-1 (DRP-1) expression were measured respectively by oxygraph, spectrophotometry and immunoblot assay. Amyloidosis was investigated employing Congo red staining. Results: One-time ICV-STZ infused animals exhibited body-weight loss and impaired cognitive ability from 14th day post-infusion. A significant loss of mitochondrial electron transport chain complex-I activity in the hippocampi and cortices was found by 14 days, and persisted up to 60 days following ICV-STZ infusion. Mitochondrial state-3 respiration was unaltered in these brain regions by 14 days, but significantly decreased from 21 days after STZ administration. DRP-1 expression was significantly increased in the hippocampi and cortices of these animals 21 days after infusion, but persisted only in the hippocampi up to 60 days. Congophilic granules indicative of amyloidosis were detected in the hippocampus by 21 days. Conclusion: Our results suggest that the non-genetic sporadic AD (sAD) rat model developed by single-time STZ-ICV infusion exhibits protein aggregation and dementia probably resulting from increased mitochondrial fragmentation and functional aberrations. The present study reinforces the validity of this model for studying pathogenesis and potential therapies of sAD.
Export Options
About this article
Cite this article as:
Paidi K. Ramesh, Nthenge-Ngumbau N Dominic, Singh Raghavendra, Kankanala Thulasi, Mehta Hina and Mohanakumar P. Kochupurackal, Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin, Current Alzheimer Research 2015; 12 (8) . https://dx.doi.org/10.2174/1567205012666150710112618
DOI https://dx.doi.org/10.2174/1567205012666150710112618 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Antipsoriatic Drug Development: Challenges and New Emerging Therapies
Recent Patents on Inflammation & Allergy Drug Discovery The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Naturalistic Measurement of Sleep in Older Adults with Amnestic Mild Cognitive Impairment: Anxiety Symptoms Do Not Explain Sleep Disturbance
Current Alzheimer Research Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment
Current Alzheimer Research Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Current Alzheimer Research Migraine and Obesity: Is There a Relationship? A Systematic Review and Meta-Analysis of Observational Studies
CNS & Neurological Disorders - Drug Targets Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Cannabis Epidemiology: A Selective Review
Current Pharmaceutical Design The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets Impact of Dietary Fats on Brain Functions
Current Neuropharmacology Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets